Aktuellt
SENASTE
As the Q4 report showed broad-based q/q improvements from the trough in Q3 we see signs of a gradual recovery for Bactiguard. However, we acknowledge the uncertainties related to the pandemic as it makes near-term performance difficult to fully assess. The launch of Zimmer Biomet-coated trauma implants in Europe coupled with the continued launch of Hydrocyn remain the key triggering events in 2021, we believe.
LÄS MER
